Compound Evidence File
#EC-2026-0083
Anadrol (Oxymetholone)
Filed under Oral Tablets. The bureau holds 160 laboratory returns for this compound from 49 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
49 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 15 May 2026 | 11 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 10 May 2026 | 6 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 7 Apr 2026 | 3 Aug 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Feb 2026 | 12 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 11 Jan 2026 | 24 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 18 May 2026 | 4 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Apr 2026 | 13 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 10.0 | 10.0 | 12 Feb 2026 | 8 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 6 Feb 2026 | 28 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 13 May 2026 | 13 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Apr 2026 | 18 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 18 May 2026 | 19 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Apr 2026 | 27 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 9.9 | 5 Jan 2026 | 27 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 7 Mar 2026 | 22 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 9.9 | 9.9 | 10.0 | 23 May 2026 | 16 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 3 Jan 2026 | 13 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Nov 2025 | 1 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 9.9 | 10 May 2026 | 17 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 9.9 | 11 Jul 2026 | 3 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 9.9 | 26 Jul 2026 | 6 Aug 2026 |
| Hunan GoodPeptides Biotech CoCASE #VI-2026-0370 | X | 1 | 9.6 | 9.6 | 9.6 | 11 Jun 2025 | 11 Jun 2025 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 9.5 | 9.5 | 9.5 | 2 Jul 2025 | 2 Jul 2025 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 9.0 | 9.0 | 9.0 | 9 Jun 2025 | 9 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 8.9 | 8.0 | 9.4 | 25 May 2026 | 25 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.6 | 7.7 | 9.3 | 25 May 2026 | 25 May 2026 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 8.5 | 8.5 | 8.5 | 27 Feb 2025 | 27 Feb 2025 |
| Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 | X | 1 | 8.5 | 8.5 | 8.5 | 20 Jun 2025 | 20 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.4 | 7.1 | 9.9 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.4 | 7.1 | 9.3 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.2 | 7.1 | 9.1 | 24 May 2026 | 24 May 2026 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 14 | 7.6 | 5.8 | 9.3 | 24 Apr 2025 | 24 May 2026 |
| Peptide SciencesCASE #VI-2026-0867 | X | 9 | 7.4 | 4.6 | 9.2 | 25 Apr 2025 | 26 Jan 2026 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 1 | 7.4 | 7.4 | 7.4 | 11 Jun 2025 | 11 Jun 2025 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 9 | 7.3 | 4.6 | 9.3 | 6 May 2025 | 24 May 2026 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 7.3 | 7.3 | 7.3 | 13 Feb 2025 | 13 Feb 2025 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 6.8 | 6.8 | 6.8 | 9 Jun 2025 | 9 Jun 2025 |
| Shanxi Qianyecao Biotech QYCCASE #VI-2026-0189 | X | 1 | 6.4 | 6.4 | 6.4 | 25 Apr 2025 | 25 Apr 2025 |
| Champion PeptideCASE #VI-2026-0909 | X | 1 | 6.2 | 6.2 | 6.2 | 3 Jul 2025 | 3 Jul 2025 |
| Atomik LabzCASE #VI-2026-0327 | X | 2 | 5.7 | 4.0 | 7.3 | 7 May 2025 | 26 Jan 2026 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 5.7 | 5.7 | 5.7 | 11 Jun 2025 | 11 Jun 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 4.7 | 4.7 | 4.7 | 3 Jul 2025 | 3 Jul 2025 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 4.5 | 4.5 | 4.5 | 24 Apr 2025 | 24 Apr 2025 |
| Verified PeptidesCASE #VI-2026-0407 | X | 1 | 4.0 | 4.0 | 4.0 | 14 Jan 2025 | 14 Jan 2025 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 1 | 3.7 | 3.7 | 3.7 | 20 Jun 2025 | 20 Jun 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.0 | 0.0 | 0.0 | 9 Jun 2025 | 9 Jun 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 7 May 2025 | 7 May 2025 |
Open any subject to view the batch-level evidence for Anadrol (Oxymetholone) alone.